Browse articles on EyeWorld.org from the Glaucoma section. EyeWorld is the award-winning member publication of ASCRS. The magazine provides news and updates from the Society as well as clinical features in the areas of cataract, refractive, cornea, glaucoma, and practice management. It publishes quarterly with editorial direction from its medical editorial board and staff.
The first-in-human trial and data for suprachoroidal outflow enhancement using a novel micro-interventional technology and first-in-class biostenting approach developed by Sean Ianchulev, MD, MPH, was published online in the British Journal of Ophthalmology in January.
“A fundamental and unanswered question concerning all MIGS devices is whether they have any measurable ability to help POAG patients retain their vision.” The authors of a study published in the American Journal of Ophthalmology sought to answer this question. The study is a post-hoc visual field analysis of the 5-year HORIZON trial.
Constance Okeke, MD, is a wife, mother, surgeon, researcher, assistant professor, consultant, and a soon-to-be two-time book author. EyeWorld caught up with her to learn more about her latest written endeavor and get some insights on what the process of book writing is like for a busy ophthalmologist.
Glaucoma Editor Nathan Radcliffe, MD, spoke about EyeWorld’s approach to glaucoma management and introduced the new Glaucoma Editor, Manjool Shah, MD.
While glaucoma specialists are likely familiar with MicroPulse Laser Therapy (Iridex) as a non-incisional, non-pharmaceutical glaucoma therapy, two physicians called it an “ace up your sleeve” and one that can be adopted by any surgeon who treats glaucoma patients.
Two physicians shared their reasons for and experiences with combining MIGS procedures.
When the term MIGS was first coined more than a decade ago, there were only a few options in the space. Since then, the MIGS space has grown significantly with many options addressing the same outflow pathway. As such, it might be time to start talking about MIGS in terms of procedural categories.
Innovation is changing the philosophy of glaucoma treatment from a drop-dependent approach to an interventional, procedure-based approach, according to Savak Teymoorian, MD. Where he’s found the philosophy shift toward acceptance of interventional glaucoma among patients has been with Durysta (bimatoprost intracameral implant, Allergan).
While some studies have found that femtosecond laser-assisted cataract surgery does not offer a significant benefit over traditional phaco, many surgeons still find it helpful in the setting of certain comorbidities. For Robert Noecker, MD, one of these is glaucoma.
Glaucoma Editor Nathan Radcliffe, MD, shares a preview of the articles in the section.